Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Patients want bigger role in ICER assessments

By BC Staff | Oct 5, 2016 | 7:00 AM GMT

Patient groups and medical product manufacturers are asking the Institute for Clinical and Economic Review (ICER) to implement major

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE